Reported 1 day ago
Eli Lilly is expected to report robust quarterly sales and profits next week, outpacing Danish competitor Novo Nordisk, which recently issued a profit warning due to lower growth expectations and competition. Analysts predict Lilly will earn $5.57 per share and revenue of $14.71 billion, primarily driven by its leading weight-loss drug Zepbound. Despite a slight dip in Lilly's stock, the company is anticipated to strengthen its market position with promising updates on its experimental obesity drug.
Source: YAHOO